Given the plasticity of melanoma cells and the capability of tumor microenvironment to produce TGF‐β (Chakravarthy et al,2018), our work also warrants further investigation of the source of TGF‐β as another approach to prevent acquisition of the therapy‐resistant mesenchymal phenotype. This evidence concerns the gene TGFB1 and neoplasm.